Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes

American Journal of Physiology - Endocrinology and Metabolism

Volumn 305, Issue 11, 2013, Pages

  Kramer, Caroline Kaercher ^a,b   Choi, Haysook ^a   Zinman, Bernard ^a,b,c   Retnakaran, Ravi ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

cell function; Diabetes; Insulin resistance; Intensive insulin therapy; Remission; Type

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR;

ADULT; ARTICLE; DIABETIC PATIENT; DIET RESTRICTION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SECRETION SENSITIVITY INDEX 2; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SCORING SYSTEM; SHORT COURSE THERAPY; TREATMENT RESPONSE;

Β-CELL FUNCTION; INSULIN RESISTANCE; INTENSIVE INSULIN THERAPY; REMISSION; TYPE 2 DIABETES;

ADULT; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; INSULIN, REGULAR, HUMAN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 84888872066     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00447.2013     Document Type: Article

References (34)

1. Baron AD, Laakso M, Brechtel G, Edelman SV. Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in noninsulin-dependent diabetic subjects. Effects of insulin therapy. J Clin Invest 87: 1186-1194, 1991.
2. Bouche C, Lopez X, Fleischman A, Cypess AM, O'Shea S, Stefanovski D, Bergman RN, Rogatsky E, Stein DT, Kahn CR, Kulkarni RN, Goldfine AB. Insulin enhances glucose-stimulated insulin secretion in healthy humans. Proc Natl Acad Sci USA 107: 4770-4775, 2010.
3. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D Jr. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42: 222-229, 1976.
4. Chen A, Huang Z, Wan X, Deng W, Wu J, Li L, Cai Q, Xiao H, Li Y. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 35: 474-481, 2012.
5. Chen H, Ren A, Hu S, Mo W, Xin X, Jia W. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract 75: 327-332, 2007.
6. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 31: 1927-1932, 2008.
7. DeVries JH. Intensive insulin therapy for type 2 diabetes at diagnosis. Lancet 1: 3-4, 2013.
8. Folli F, Okada T, Perego C, Gunton J, Liew CW, Akiyama M, D'Amico A, La Rosa S, Placidi C, Lupi R, Marchetti P, Sesti G, Hellerstein M, Perego L, Kulkarni RN. Altered insulin receptor signaling and beta-cell dynamics in type 2 diabetes mellitus. PLoS One 6: e28050, 2011.
9. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34: 222-234, 1985.
10. Ginsberg H, Rayfield EJ. Effect of insulin therapy on insulin resistance in type II diabetic subjects. Evidence for heterogeneity. Diabetes 30: 739-745, 1981.
11. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 16: 965-980, 1997.
12. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 292: E829-E835, 2007.
13. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 52: 1003-1012, 2009.
14. Kayaniyil S, Retnakaran R, Harris SB, Vieth R, Knight JA, Gerstein HC, Perkins BA, Zinman B, Hanley AJ. Prospective associations of vitamin D with β-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes 60: 2947-2953, 2011.
15. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy and its impact on type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 1: 28-34, 2013.
16. Kulkarni RN, Brüning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96: 329-339, 1999.
17. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 27: 2597-2602, 2004.
18. Liu L, Wan X, Liu J, Huang Z, Cao X, Li Y. Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technol Ther 14: 756-761, 2012.
19. Lopez X, Cypess A, Manning R, O'Shea S, Kulkarni RN, Goldfine AB. Exogenous insulin enhances glucose-stimulated insulin response in healthy humans independent of changes in free fatty acids. J Clin Endocrinol Metab 96: 3811-3821, 2011.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
21. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
22. Meneghini LF. Early insulin treatment in type 2 diabetes: what are the pros? Diabetes Care 32, Suppl 2: S266-S269, 2009.
23. O'Gorman CS, Syme C, Lang J, Bradley TJ, Wells GD, Hamilton JK. An evaluation of early cardiometabolic risk factors in children and adolescents with Turner Syndrome. Clin Endocrinol 78: 907-913, 2013.
24. Opsteen C, Qi Y, Zinman B, Retnakaran R. Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. J Eval Clin Pract 18: 256-261, 2012.
25. Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet 371: 1725-1726, 2008.
26. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 16: 1901-1907, 2008.
27. Retnakaran R, Qi Y, Goran MI, Hamilton JK. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 26: 1198-1203, 2009.
28. Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B. Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care 33: 1798-1804, 2010.
29. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 12: 65-71, 2010.
30. Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care 34: 1601-1604, 2011.
31. Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function. Diabetes Obes Metab 14, Suppl 3: 161-166, 2012.
32. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28: 187-218, 2007.
33. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371: 1753-1760, 2008.
34. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 376: 103-111, 2010.